Answers are grounded in this paper and cite their sources.
Letters5 December 2000Cholesterol and Lipoprotein Levels as Predictors of Response to Interferon for Hepatitis CHidenori Toyoda, MD and Takashi Kumada, MDHidenori Toyoda, MDFujita Health University, School of Medicine; Toyoake Aichi, 470-1192 Japan (Toyoda)Ogaki Municipal Hospital; Ogaki Gifu, 503-8502 Japan (Kumada) and Takashi Kumada, MDFujita Health University, School of Medicine; Toyoake Aichi, 470-1192 Japan (Toyoda)Ogaki Municipal Hospital; Ogaki Gifu, 503-8502 Japan (Kumada)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-11-200012050-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Minuk and colleagues (1) suggest that serum cholesterol and low-density lipoprotein (LDL) cholesterol are predictors of response to interferon therapy for chronic hepatitis C. To test this finding, we retrospectively compared pretreatment serum cholesterol levels between responders and nonresponders among 63 patients who had participated in our randomized trial (2).As Minuk and colleagues indicated, responders had higher serum cholesterol levels than nonresponders (4.83 ± 0.92 mmol/L [186.8 ± 35.7 mg/dL] vs. 4.13 ± 0.74 mmol/L [159.8 ± 28.7 mg/dL]; P = 0.003). However, a previous study reported a decrease in serum cholesterol and LDL cholesterol levels that was ...References1. Minuk GY, Weinstein S, Kaita KD. Serum cholesterol and low-density lipoprotein cholesterol levels as predictors of response to interferon therapy for chronic hepatitis C [Letter]. Ann Intern Med. 2000;132:761-2. LinkGoogle Scholar2. Toyoda H, Nakano S, Kumada T, Takeda II, Sugiyama K, Osada T, et al . Effect of daily administration period of natural α-interferon in patients with chronic hepatitis C. Am J Gastroenterol. 1996;91:743-7. MedlineGoogle Scholar3. Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med. 1997;157:792-6. CrossrefMedlineGoogle Scholar4. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al . Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-5. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Hidenori Toyoda, MD; Takashi Kumada, MDAffiliations: Fujita Health University, School of Medicine; Toyoake Aichi, 470-1192 Japan (Toyoda)Ogaki Municipal Hospital; Ogaki Gifu, 503-8502 Japan (Kumada) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSerum Cholesterol and Low-Density Lipoprotein Cholesterol Levels as Predictors of Response to Interferon Therapy for Chronic Hepatitis C Gerald Y. Minuk , Sharon Weinstein , and Kelly D. Kaita Metrics Cited byIntensified Peginterferon α-2a Dosing Increases Sustained Virologic Response Rates in Heavy, High Viral Load Hepatitis C Genotype 1 Patients With High Low-density LipoproteinFactors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patientsIL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infectionReversal of Hypolipidemia in Chronic Hepatitis C Patients After Successful Antiviral TherapySerum cholesterol and statin use predict virological response to peginterferon and ribavirin therapyInterferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infectionAssociation between lipoprotein subfraction profile and the response to hepatitis C treatment in Japanese patients with genotype 1bThe individual and combined influence of HIV and hepatitis C virus on dyslipidaemia in a high-risk Hispanic populationInsulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patientsBaseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patientsBaseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis CCorrelation between beta-lipoprotein levels and outcome of hepatitis C treatmentHepatitis C and steatosis: a reappraisalHepatitis C Virus–Associated Hypobetalipoproteinemia Is Correlated With Plasma Viral Load, Steatosis, and Liver Fibrosis 5 December 2000Volume 133, Issue 11Page: 921KeywordsCholesterolHepatitis CInterferonsLipoproteinsLiverLiver diseasesLiver fibrosisLow density lipoproteinPatientsRandomized trials ePublished: 5 December 2000 Issue Published: 5 December 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
Hidenori Toyoda (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: